Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6377

Provisional Schedule

Committee meeting 06 November 2024
Expected publication 29 January 2025

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Novartis Pharmaceuticals (ruxolitinib)
Others Department of Health and Social Care
  NHS England
Patient carer groups Anthony Nolan
  Leukaemia Care
Professional groups British Society of Blood and Marrow Transplantation and Cellular Therapy
  Royal College of Physicians
Associated public health groups None
Comparator companies Pfizer (sirolimus) (confidentiality agreement not signed, not participating)
  Roche Products (mycophenolate mofetil) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (mycophenolate mofetil) (confidentiality agreement not signed, not participating)
  Teva Pharma (mycophenolate mofetil) (confidentiality agreement not signed, not participating)
  Therakos UK (confidentiality agreement signed, participating)
  Tillomed Laboratories (mycophenolate mofetil) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups None

Timeline

Key events during the development of the guidance:

Date Update
15 April 2024 Invitation to participate
07 March 2024 - 20 March 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6377
07 March 2024 In progress. Scoping commenced.
01 February 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
01 February 2024 The appraisal is expected to start during March 2024 with a consultation on the draft scope. It is then anticipated that the final scope will be released along with an invitation to participate in the appraisal during mid-April 2024.

For further information on our processes and methods, please see our CHTE processes and methods manual